IGEA announces changes in its board

Hoofddorp, the Netherlands, 21 October 2020. IGEA Pharma N.V. (SIX: IGPH) today announced the resignation of Mr. Mark De Simone from the board of directors for professional reasons related to other executive activities.

Read More

IGEA and Blue Sky Natural Resources to combine businesses

Hoofddorp, the Netherlands, 8 August 2020. IGEA Pharma N.V. (SIX: IGPH) today announced the signing of a letter of intent, binding upon the parties in terms, with Blue Sky Natural Resources LTD (“BSNR”), a privately held company specialized in transforming vegetable matrices into innovative and high tech value products for the health, nutraceutical and cosmeceutical industry, to combine the two companies’ businesses, subject to the approval by both companies’ respective general meetings and certain other closing conditions as detailed below. The transaction is structured through a contribution in-kind by the BSNR shareholders of at least 75% of the BSNR shares into IGEA by subscribing newly issued shares in a dedicated share capital increase of IGEA. The combination will create an EU headquartered and SIX-listed company with an innovative early-stage commercial and a strong development pipeline focusing on health prevention and nutraceutical solutions including hemp, ikuvia and other vegetable matrices extracts from CO2 supercritical technology.

Read More

IGEA announces changes in its board

Hoofddorp, the Netherlands, 7 August 2020. IGEA Pharma N.V. (SIX: IGPH) today announced the resignation of Mr. Marco Seniga from its board of directors for personal reasons related to his retirement. Seniga also terminated his engagement with the company as director of marketing and
sales.

Read More

IGEA announces changes in its board

Hoofddorp, the Netherlands, 2 June 2020. IGEA Pharma N.V. (SIX: IGPH) today announced the nomination of Mr. Lieven Baten for election as non-executive director of IGEA at the upcoming general meeting on 3 July 2020. Lieven Baten is a partner at Acalis, with which IGEA has previously signed a strategic partnership for the distribution of its products.

Read More

Miami University confirms high quality of IGEA’s COVID-19 rapid test

Hoofddorp, the Netherlands, 6 May 2020. IGEA Pharma N.V. (SIX: IGPH) today announced that an evaluation by the Histocompatibility Laboratories, Department of Surgery, University of Miami – Miller School of Medicine suggests that the IGEA’s COVID-19 antibody rapid test appears to be superior to an established ELISA procedure in detecting IgM and IgG antibodies.

Read More